missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Mouse Syndecan-1/CD138 Antibody, R&D Systems™
Rat Monoclonal Antibody
Brand: R&D Systems MAB29661
This item is not returnable.
View return policy
Description
Syndecan-1/CD138 Monoclonal specifically detects Syndecan-1/CD138 in Mouse samples. It is validated for Western Blot, Immunohistochemistry, Immunoprecipitation.
Specifications
| Syndecan-1/CD138 | |
| Monoclonal | |
| LYOPH | |
| Western Blot 1 ug/mL, Immunohistochemistry 1-25 ug/mL, Immunoprecipitation 25 ug/mL | |
| P18828 | |
| SDC1 | |
| Mouse myeloma cell line NS0-derived recombinant mouse Syndecan-1/CD138 isoform 1 Gln18-Glu252 (predicted) Accession # P18828 | |
| 100 μg | |
| Primary | |
| Detects mouse Syndecan-1/CD138 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human Syndecan-1, recombinant mouse (rm) Syndecan-2, rmSyndecan-3, or rmSyndecan-4 is observed. | |
| Mouse | |
| Purified |
| Western Blot, Immunohistochemistry, Immunoprecipitation | |
| 320611 | |
| Unconjugated | |
| Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
| CD138, CD138 antigen, SDC, SDC1, SYND1heparan sulfate proteoglycan fibroblast growth factor receptor, syndecan, syndecan 1, syndecan proteoglycan 1, syndecan-1, Syndecan1 | |
| Rat | |
| Protein A or G purified from hybridoma culture supernatant | |
| RUO | |
| 6382 | |
| Reconstitute at 0.5 mg/mL in sterile PBS. | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
| IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction